Polymer Capital Management HK LTD Invests $2.43 Million in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Polymer Capital Management HK LTD purchased a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the 4th quarter, Holdings Channel.com reports. The fund purchased 10,313 shares of the biopharmaceutical company’s stock, valued at approximately $2,427,000.

A number of other large investors have also recently added to or reduced their stakes in the company. Regeneron Pharmaceuticals Inc. acquired a new stake in Alnylam Pharmaceuticals during the fourth quarter worth approximately $1,045,822,000. Norges Bank acquired a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter valued at $577,941,000. Raymond James Financial Inc. bought a new position in Alnylam Pharmaceuticals in the fourth quarter valued at about $65,295,000. Jennison Associates LLC bought a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth $61,160,000. Finally, Proficio Capital Partners LLC increased its holdings in Alnylam Pharmaceuticals by 25,929.6% in the 4th quarter. Proficio Capital Partners LLC now owns 193,660 shares of the biopharmaceutical company’s stock worth $45,570,000 after purchasing an additional 192,916 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 1,213 shares of the company’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $255.17, for a total value of $309,521.21. Following the sale, the chief executive officer now directly owns 81,526 shares of the company’s stock, valued at approximately $20,802,989.42. This represents a 1.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Jeffrey V. Poulton sold 967 shares of the company’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $255.17, for a total value of $246,749.39. Following the completion of the sale, the chief financial officer now owns 32,786 shares in the company, valued at approximately $8,366,003.62. This represents a 2.86 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 71,234 shares of company stock valued at $19,958,097. Insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Stock Down 10.1 %

NASDAQ ALNY opened at $235.74 on Friday. Alnylam Pharmaceuticals, Inc. has a one year low of $141.98 and a one year high of $304.39. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. The stock has a 50 day moving average price of $259.03 and a 200-day moving average price of $260.23. The company has a market capitalization of $30.67 billion, a P/E ratio of -108.64 and a beta of 0.30.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). As a group, equities analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have commented on ALNY shares. Citigroup lifted their target price on Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the stock a “buy” rating in a report on Friday, March 21st. StockNews.com downgraded Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, March 21st. Wells Fargo & Company lifted their price objective on shares of Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the company an “equal weight” rating in a report on Friday, March 21st. JPMorgan Chase & Co. raised Alnylam Pharmaceuticals from a “neutral” rating to an “overweight” rating and increased their price target for the company from $280.00 to $328.00 in a research report on Monday, March 24th. Finally, William Blair restated an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Friday, March 21st. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-one have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $316.25.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.